# Evotec SE (EVO)

> Source: Nexqual · https://nexqual.com/EVO · data as of 2026-10-23 16:58 UTC · cite as "Nexqual, Evotec SE (EVO), nexqual.com/EVO" · informational, not investment advice.

**Price:** USD 1.51 (-1.92% today) · US market open, as of October 23, 2026 at 16:58 UTC; quotes may be delayed. Prev close 1.54 · day 1.5–1.53 · 52w 1.33–4.27 · market cap $537M · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 4.22 (range 2.01–6.66).
- Total return with dividends: 1Y -62.6% vs S&P 500 +14.6%; 5Y -93.7% vs S&P 500 +77.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.32, revenue estimate $139M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 4.22 (low 2.01, high 6.66).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | HC Wainwright & Co. | Reiterated | Buy | $4 |
| 2026-07-15 | HC Wainwright & Co. | Target lowered | Buy | $7 → $4 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -62.6% | -93.7% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -62.6% | -42.5% |
| Volatility (annualized) | 57.8% | 58.8% |
| Max drawdown | -67.5% (Oct 2025→Oct 2026) | -94.3% (Oct 2021→Oct 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.34 -2.33% · SUPN (Supernus Pharmaceuticals, Inc.) USD 40.42 -3.92% · HCM (HUTCHMED (China) Limited) USD 14.4 +0.84% · LQDA (Liquidia Corporation) USD 41.25 +3.93% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.71 -3.01% · INDV (Indivior Pharmaceuticals, Inc.) USD 34.37 -2.72%

## More
Full page: https://nexqual.com/EVO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in EVO's own 20-F filed 2026-04-08 (https://www.sec.gov/Archives/edgar/data/1412558/000110465926040767/evo-20251231x20f.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Novo Nordisk (NVO) | "Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"),…" |
| Partner | Sandoz | "Following changes in our financial profile, the facility was no longer aligned with our evolving funding strategy, At the end of 2025, we completed a share purchase agreement with Sandoz for the sale of 100% of the share…" |
| Partner | Evotec Biologics | "Following changes in our financial profile, the facility was no longer aligned with our evolving funding strategy, At the end of 2025, we completed a share purchase agreement with Sandoz for the sale of 100% of the share…" |
| Partner | Eli Lilly (LLY) | "Based on the strength of our molecular CKD patient database, we have built four partnerships in kidney diseases in the last almost ten years with prominent pharmaceutical companies such as Bayer, Vifor (now "CSL Vifor"),…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.32 | $-0.20 | +53.7% | $138.7M | 2 |
| Next quarter (ends 2026-12-31) | $-0.24 | $-0.04 | +585.7% | $144.8M | 1 |
| Current fiscal year (ends 2026-12-31) | $-1.48 | $-1.10 | +33.5% | $598.8M | 2 |
| Next fiscal year (ends 2027-12-31) | $0.07 | $-0.15 | -145.2% | $721.4M | 1 |